.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Metropolis diagnostic growth significantly influenced the company\'s latest financial results for the March quarter. On Wednesday, the lab chain reported a 74 per cent rise in consolidated profit after tax. This growth resulted in a profit of Rs 50.96 crore, up from Rs 29.23 crore in the previous fiscal year. Consequently, the company demonstrated strong resilience and operational efficiency in a competitive market.
Several factors contributed to this surge, including a 23 per cent increase in year-on-year revenue. The company expanded its network to over 5,000 centres across India to meet rising diagnostic needs. Furthermore, Managing Director Surendran Chemmenkotil noted that healthy patient volumes and improved realisations drove this success. Moreover, the brand achieved these results without increasing prices during the final quarter.
Total consolidated revenue reached Rs 424.68 crore, while expenses also rose to Rs 363.19 crore. However, the operational efficiency drive offset these higher costs effectively. Therefore, the board approved a second dividend of Re 1 per share for the financial year. This decision reflects a positive outlook on the company\'s future sustainability and market position.
Q1: What drove the 74% profit increase for Metropolis Healthcare?
The growth was primarily driven by robust demand, network expansion beyond 5,000 centres, healthy patient volumes, and an improved service mix without price hikes in Q4.
Q2: What is the latest dividend announced by the company?
The board of Metropolis Healthcare has approved a second dividend of Re 1 per share for the 2025-26 financial year following its strong performance.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Metropolis Healthcare reports a 74% profit rise to Rs 50.96 cr in Q4 FY26, driven by network expansion and strong patient volumes across 5,000 centres....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
